Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an ...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Medicare covers immunotherapy treatment for cancer. Out-of-pocket costs will vary, depending on the Medicare plan a person has and whether or not they have supplemental insurance. If a person has ...

In a clinical trial known as EPCORE NHL-2, the researchers showed the benefit of combining chemotherapy with immunotherapy for DLBCL. The results, published in the journal Blood, offer new hope ...

Kim, MD, MBA, discussed with participants utilizing chemoradiation and immunotherapy for patients with non–small ... with locally advanced non–small cell lung cancer treated with cemiplimab. According ...

Calcipotriol plus 5-FU immunotherapy activates Th2 immunity, releasing IL-24 cytokines to suppress skin cancer development in patients with actinic keratosis. The combination therapy significantly ...

Cemiplimab significantly improves DFS in patients with high-risk CSCC post-surgery, reducing recurrence or death risk by 68% compared with placebo. The C-POST trial marks the first immunotherapy ...